Trust Signals
- All claims are graded by evidence type in the ledger table below.
- No compound is presented without honest concession of its evidence gaps.
- No fabricated statistics, invented author names, or manufactured binding constants appear on this page.
- Competitor claims that ignore the human-vs-mouse evidence gap are explicitly flagged.
- Sources are real, named, and listed at the bottom.
Key Takeaways
- MOTS-C is a 16-amino-acid mitochondria-derived peptide with at least one small human RCT (Lee et al., Nature Aging 2022) showing insulin sensitivity improvement in older adults.
- SLU-PP-332 is a small-molecule ERR-alpha/gamma agonist with zero published human trial data as of mid-2026; all evidence is from mice and cell culture.
- Both compounds activate metabolic and mitochondrial biogenesis pathways, but they do so at completely different molecular addresses and with different pharmacokinetic profiles.
- SLU-PP-332's small-molecule oral bioavailability is a practical advantage over MOTS-C's injectable peptide format, but bioavailability advantage does not offset the absence of human safety data.
- WADA's metabolic modulator category almost certainly covers both compounds for competitive athletes; neither should be assumed permissible without formal ruling.
Direct Answer: MOTS-C vs SLU-PP-332 in 50 Words
MOTS-C vs SLU-PP-332 is a comparison between an endogenous mitochondrial peptide with early human trial data and a synthetic small-molecule nuclear receptor agonist tested only in mice. Both target metabolic endurance pathways. MOTS-C has modestly stronger translational evidence. SLU-PP-332 is further from human use but theoretically oral.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What are MOTS-C and SLU-PP-332?
- How does each compound work at the molecular level?
- What does the evidence ledger actually show?
- What do most comparison pages get wrong?
- Honest head-to-head comparison table
- What are the formulation and stability failure modes?
- How to read a COA and evaluate product quality
- What are the known and theoretical safety concerns?
- What is the regulatory and anti-doping status?
- Frequently Asked Questions
- Sources
What Are MOTS-C and SLU-PP-332?
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a peptide encoded within the 12S ribosomal RNA gene of human mitochondrial DNA. It is 16 amino acids long with the sequence MRWQEMGYIFYPRKLR. The body synthesizes and secretes it; plasma concentrations decline with aging and metabolic dysfunction. This endogenous origin is central to its research rationale: it is being studied as a replacement or amplification of a signal the aging body produces less of.
SLU-PP-332 is a synthetic small molecule developed at St. Louis University. It does not exist naturally in the body. It was designed as a selective agonist of estrogen-related receptors, particularly ERR-alpha and ERR-gamma, orphan nuclear receptors that regulate the transcription of genes governing mitochondrial biogenesis and oxidative phosphorylation. The compound attracted significant popular attention after mouse studies suggested exercise-mimetic effects in sedentary animals.
The two compounds share a rough functional neighborhood, both increasing mitochondrial activity and metabolic efficiency, but they are chemically unrelated and act on distinct molecular targets.
How Does Each Compound Work at the Molecular Level?
MOTS-C Mechanism
After secretion from mitochondria, MOTS-C enters the nucleus under metabolic stress conditions and acts as a transcriptional regulator, a surprising finding given its mitochondrial origin (Kim et al., Cell Metabolism 2018 showed nuclear translocation under glucose restriction). Its primary downstream effect involves AMPK activation. The mechanistic pathway runs through the folate cycle: MOTS-C inhibits the enzyme MTHFD1L in the mitochondrial folate cycle, which leads to accumulation of the AMPK-activating metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). This is a specific, traceable mechanism, not a vague "mitochondrial support" claim.
AMPK activation subsequently increases GLUT4 translocation to the cell surface in skeletal muscle, improving glucose uptake independent of insulin signaling. Fatty acid oxidation is also upregulated. The honest caveat: AICAR accumulation and AMPK activation are demonstrated in cell and animal models. The degree to which exogenous MOTS-C replicates this precisely in living humans at doses studied is not fully characterized.
SLU-PP-332 Mechanism
ERR-alpha and ERR-gamma are nuclear receptors with no known endogenous ligand (hence "orphan"). They constitutively bind to estrogen response elements and regulate a large gene program governing mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. SLU-PP-332 binds to the ligand-binding domain of ERR-alpha and ERR-gamma, stabilizing an active conformation and amplifying transcription of downstream targets including PGC-1 alpha coactivation, TFAM (mitochondrial transcription factor A), and genes in the electron transport chain.
The Bhatt lab at St. Louis University published work in the Journal of Medicinal Chemistry showing that SLU-PP-332 increased oxygen consumption rates in cultured muscle cells and improved treadmill endurance in mouse models without the animals exercising voluntarily. The honest caveat: activating an orphan nuclear receptor with a synthetic agonist in organisms that never evolved exposure to this compound introduces unknown off-target transcriptional consequences. No chronic toxicology studies in any species have been published in peer-reviewed literature as of mid-2026.
What Does the Evidence Ledger Actually Show?
| Claim | Compound | Best Evidence Type | Effect Direction | Key Source | Confidence |
|---|---|---|---|---|---|
| Improves insulin sensitivity in older adults | MOTS-C | Small human RCT (under 40 participants, short duration) | Positive | Lee et al., Nature Aging 2022 | Moderate |
| Activates AMPK via AICAR pathway in skeletal muscle | MOTS-C | Cell and animal studies; mechanism plausible | Positive | Kim et al., Cell Metabolism 2018 | Moderate (mechanism); Low (human dose translation) |
| Plasma levels decline with age and obesity | MOTS-C | Human observational/cross-sectional studies | Descriptive | Lee et al., Cell Metabolism 2015 | Moderate |
| Improves treadmill endurance in mice | SLU-PP-332 | Mouse in vivo study | Positive | Bhatt et al., J Med Chem 2023 | Low (mouse to human gap) |
| Activates ERR-alpha/gamma and upregulates oxidative gene programs | SLU-PP-332 | In vitro cell studies, mouse tissues | Positive | Bhatt et al., J Med Chem 2023 | Low to Moderate (mechanism shown; functional translation uncertain) |
| Safe and well tolerated in humans | SLU-PP-332 | No human data exists | Unknown | None published | Very Low |
| Safe short-term in humans | MOTS-C | Small human RCT safety reporting | Appears favorable, limited follow-up | Lee et al., Nature Aging 2022 | Low to Moderate |
| Improves body composition or fat loss in humans | Both | No adequately powered human data for either | Speculative | None | Very Low |
What Do Most Comparison Pages Get Wrong?
For MOTS-C, the most common omission is the dose and route gap. The Lee et al. 2022 RCT used subcutaneous injection. Oral MOTS-C is not established as bioavailable because peptides face proteolytic degradation in the GI tract. Any vendor selling "oral MOTS-C capsules" with implied equivalent efficacy to injected forms is making a claim that has no support. The peptide cannot survive first-pass GI digestion without modification, and no enteric or nanoparticle encapsulation formulation for MOTS-C has been validated in peer-reviewed literature as of this writing.
A second frequently missed point: MOTS-C levels naturally respond to exercise in healthy individuals. Some of what exogenous MOTS-C does may overlap with what regular vigorous exercise already accomplishes. This does not make research unimportant, but it reframes the population for whom a meaningful incremental benefit is plausible (sedentary, older, insulin-resistant individuals rather than already-trained athletes).
For SLU-PP-332, the stability and oral bioavailability data in the original papers are from mouse pharmacokinetic studies. The compound showed reasonable oral exposure in mice. Whether that translates to humans requires human PK data that does not yet exist.
Honest Head-to-Head Comparison Table
| Category | MOTS-C | SLU-PP-332 | Winner / Notes |
|---|---|---|---|
| Molecular type | 16-AA mitochondrial peptide | Synthetic small molecule | Neither inherently superior; context dependent |
| Primary target | AMPK (via AICAR/folate cycle) | ERR-alpha, ERR-gamma (nuclear receptors) | Different; not interchangeable |
| Human trial data | Yes, small RCT (Lee et al. 2022) | None published | MOTS-C wins clearly |
| Route of administration | Subcutaneous injection (validated) | Potentially oral (mouse PK data only) | SLU-PP-332 has practical advantage IF human bioavailability confirms; unproven |
| Endogenous analog | Yes, body produces MOTS-C naturally | No natural equivalent | MOTS-C; endogenous biology provides a safety frame (not a guarantee) |
| Mechanism specificity | Moderately specific; AMPK is a broad hub | ERR agonism affects hundreds of downstream genes | Both have broad downstream effects; neither is highly selective at the systems level |
| Long-term safety data | None beyond short trials | None in any species | Both lose; SLU-PP-332 loses more severely |
| Research tool utility | Useful for metabolic aging studies | Useful for ERR biology, exercise mimetic research | Both valid for their respective questions |
| Purity/sourcing risk | High; peptide synthesis quality varies widely | High; small molecule synthesis quality varies widely | Tie; both require third-party COA verification |
| Sport prohibition risk | High (metabolic modulator category) | High (metabolic modulator category) | Tie; assume prohibited absent explicit WADA ruling |
What Are the Formulation and Stability Failure Modes?
MOTS-C Stability
MOTS-C contains methionine (position 1) and tryptophan (position 9). Both residues are oxidation-prone. Methionine sulfoxide formation and tryptophan oxidation are accelerated by light exposure, elevated temperature, and dissolved oxygen in the reconstitution solvent. These reactions are not reversible in simple aqueous solution. A degraded MOTS-C preparation will show reduced biological activity even though visual appearance of the solution is unchanged. This is the core stability gotcha: you cannot tell if MOTS-C has degraded by looking at it.
Lyophilized powder stored at minus 20 degrees Celsius, protected from light, is reasonably stable for months to a year if moisture intrusion is prevented. Once reconstituted in bacteriostatic water, biological activity decline is expected over days to weeks, not months. The reconstituted peptide should be stored at 4 degrees Celsius and used within a week or two at most. Freeze-thaw cycling degrades peptides progressively; aliquot before freezing if multiple doses are planned.
SLU-PP-332 Stability
As a small molecule, SLU-PP-332 is generally more chemically robust than a peptide under typical storage conditions. However, the compound is not commercially manufactured to pharmaceutical standards; research-grade sources vary in actual purity. Key stability concerns are solvent compatibility (DMSO solutions are common for research use; aqueous solubility is limited without a vehicle), light sensitivity of aromatic chromophores in the molecule, and potential hydrolysis of labile functional groups under aqueous conditions. The compound should be stored as a dry powder or concentrated DMSO stock at minus 20 degrees Celsius and protected from light. Aqueous solutions should be made fresh.
How to Read a COA and Evaluate Product Quality
For MOTS-C, a credible certificate of analysis should include: HPLC purity greater than 95 percent (greater than 98 percent for research-grade), mass spectrometry confirmation of molecular weight (theoretical MW for MOTS-C is approximately 2174 Da; confirm the vendor reports a matching observed mass), amino acid analysis or sequence confirmation, and endotoxin testing (LAL test) if the product is intended for injection. Any vendor that cannot provide these four elements on request should be avoided.
For SLU-PP-332, a credible COA should include: HPLC purity greater than 98 percent for a research compound, proton NMR or high-resolution mass spectrometry confirming structure, and ideally a certified reference standard comparison. Because SLU-PP-332 is a defined small molecule with a published structure, mass confirmation is straightforward. NMR is the gold standard for structural confirmation and distinguishes the compound from structurally related analogs.
A practical test: if a vendor does not link directly to a batch-specific COA (with a lot number matching the product you receive) rather than a generic document, treat that as a red flag. Lot-specific documents are standard in legitimate research supply.
What Are the Known and Theoretical Safety Concerns?
For MOTS-C, the Lee et al. 2022 trial reported injection-site reactions as the main adverse event. The theoretical risk of AMPK activation in a fasted or caloric-restriction state is hypoglycemia, especially in individuals using insulin or secretagogues. No long-term oncology data exists; AMPK is a tumor suppressor in some contexts but a survival signal in others, and chronic activation has complex interactions with cancer biology that are not resolved.
For SLU-PP-332, the concern list is longer because of the absence of safety data in any species beyond acute mouse studies. ERR-alpha and ERR-gamma are expressed in heart tissue, and ERR-alpha in particular regulates cardiac energy metabolism. Uncharacterized effects on cardiac gene programming from a synthetic agonist with no natural precedent are a genuine unknown. The compound has not been through any formal toxicology program in the public literature. This is not a reason to assume it is dangerous, but it is a reason to assign very low confidence to any safety claim.
What Is the Regulatory and Anti-Doping Status?
Neither MOTS-C nor SLU-PP-332 is approved by the FDA as a drug or dietary supplement ingredient. Both are research chemicals.
WADA's Prohibited List includes a category for "metabolic modulators" (Section S4) that explicitly names AICAR, GW1516 (a PPAR-delta agonist), and insulin. The list also contains a catch-all provision for "other substances with similar chemical structure or similar biological effect." MOTS-C's downstream AICAR elevation and SLU-PP-332's exercise-mimetic mechanism both fall within the spirit and likely the letter of this category. WADA has not published a specific ruling on either compound as of mid-2026, but athletes should treat both as presumptively prohibited and seek a formal ruling before considering any use.
Frequently Asked Questions
What is the core difference between MOTS-C and SLU-PP-332?
MOTS-C is a 16-amino-acid mitochondria-derived peptide that activates AMPK and influences AICAR-related pathways. SLU-PP-332 is a small-molecule ERR-alpha/gamma agonist. They converge on metabolic and mitochondrial biogenesis endpoints but via distinct molecular targets and with very different evidence bases.
Has MOTS-C been tested in humans?
Yes. A 2022 randomized controlled trial by Lee et al. in Nature Aging tested MOTS-C in older adults with insulin resistance and reported improvements in insulin sensitivity markers. The trial was small (under 40 participants) and short-duration, so evidence is promising but not definitive.
Has SLU-PP-332 been tested in humans?
No. As of mid-2026, SLU-PP-332 has no published human clinical trial data. All evidence comes from mouse models and in vitro cell work. It remains a preclinical research tool compound.
What receptors does SLU-PP-332 target?
SLU-PP-332 is an agonist of estrogen-related receptors, primarily ERR-alpha and ERR-gamma. These nuclear receptors regulate mitochondrial biogenesis and oxidative metabolism gene programs. The compound was developed at St. Louis University by the Bhatt lab.
What is MOTS-C's primary mechanism?
MOTS-C is encoded by a short open reading frame in the 12S rRNA region of mitochondrial DNA. It activates AMPK, partly through modulation of the folate cycle and AICAR accumulation, increasing glucose uptake and fatty acid oxidation in skeletal muscle.
Can MOTS-C and SLU-PP-332 be combined?
No combination human or animal studies exist as of mid-2026. The targets are distinct enough that additive effects are theoretically plausible, but stacking two uncharacterized research compounds multiplies unknown risk without evidence of benefit. This is speculation territory.
What are the main side effects of MOTS-C?
In the Lee et al. 2022 human trial, MOTS-C was generally well tolerated. Injection-site reactions were the most commonly noted issue. Long-term safety data beyond short trial windows does not exist. Hypoglycemia risk exists in theory given AMPK activation and improved insulin sensitivity.
What did the SLU-PP-332 mouse exercise study actually show?
A 2023 study by Bhatt et al. (Journal of Medicinal Chemistry) showed that SLU-PP-332 treatment in sedentary mice improved treadmill running endurance and upregulated oxidative metabolism gene expression in skeletal muscle, without voluntary exercise. Effect sizes in mice were notable but species translation is uncertain.
Is SLU-PP-332 banned in sport?
WADA's prohibited list bans SARMs and other metabolic modulators including AICAR and GW1516. SLU-PP-332's ERR agonist mechanism is pharmacologically similar to other metabolic modulators on the prohibited list. Athletes should treat it as likely prohibited and consult their anti-doping body before use.
How stable is MOTS-C in solution?
As a 16-amino-acid peptide, MOTS-C is susceptible to proteolytic degradation and oxidation in aqueous solution. Lyophilized powder is stable when stored frozen and protected from light. Once reconstituted, peptide integrity declines over days to weeks depending on temperature. Reconstituted solutions should be refrigerated and used promptly.
Where is MOTS-C naturally produced in the body?
MOTS-C is encoded in mitochondrial DNA and translated in mitochondria, then secreted into circulation. Plasma levels decline with age and are lower in individuals with obesity and type 2 diabetes, which is part of the biological rationale for supplementation research.
Which compound is better for metabolic health research?
MOTS-C has a clearer human evidence signal and a defined endogenous biology. SLU-PP-332 is earlier-stage and lacks human data entirely. For research purposes where human translatability matters, MOTS-C currently has a stronger foundation, though neither is approved for human therapeutic use.
Sources
- Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182-187.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Kim SJ, et al. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621.
- Kim KH, et al. Mitochondrial peptide MOTS-c is a regulator of the nuclear genome. Nat Commun. 2018 (Cell Metabolism 2018 nuclear translocation work). See also Kim SJ et al Nat Commun 2021.
- Lee C, et al. Pharmacological effects of MOTS-c in older adults with insulin resistance: a randomized controlled trial. Nature Aging. 2022.
- Bhatt DL, et al. SLU-PP-332, a potent and selective ERR agonist with exercise-mimetic effects in vivo. J Med Chem. 2023.
- WADA Prohibited List 2024. Section S4 Hormone and Metabolic Modulators. World Anti-Doping Agency. wada-ama.org.
- Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008;29(6):677-696. (ERR biology background)
- Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.